Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Randomized, Double-blinded Assessment of Tecfidera in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)

Next Previous
Search
Trial Profile

Multi-center, Randomized, Double-blinded Assessment of Tecfidera in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms ARISE

Most Recent Events

  • 18 Nov 2022 Primary endpoint (the time to onset of clinical symptoms attributable to a CNS demyelinating event within a follow-up period of 96 weeks ) has been met, according to Results published in the Annals of Neurology.
  • 18 Nov 2022 Results published in the Annals of Neurology
  • 26 Oct 2022 According to a Biogen media release, data from this study presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), will be presented in the late-breaking section

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top